Drug intelligence / Profile preview

Serquit Plus

Development stage: Unknown
Lead developer: Ardent Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

**Serquit Plus** is an oral fixed-dose tablet combination of **sertraline** and **clonazepam** from Ardent Life Sciences for depression and anxiety. Sertraline is a selective serotonin reuptake inhibitor that inhibits the serotonin transporter, while clonazepam is a benzodiazepine positive allosteric modulator of gamma-aminobutyric acid type A receptors, providing anxiolytic and sedative effects. Ardent Life Sciences lists Serquit Plus in its antidepressant and anxiolytic portfolio. ([ardentlifesciences.com](https://www.ardentlifesciences.com/))

Brand names: Serquit Plus
Other names: sertraline + clonazepamSertraline + Clonazepam tablets

Targets

GABAA (Gamma-aminobutyric acid receptor)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on Serquit Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Serquit Plus.

Explore the full profile